FAFabiana Michelsen de Andrade

Fabiana Michelsen de Andrade

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fabiana Michelsen de Andrade has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Depression and Memory Decline in the Elderly

    by Andréa G. Machado, Paola Andressa L. Dornelles, Fabiana M. Andrade, Marilu Fiegenbaum, Analuiza C. Pádua, Alcyr A. Oliveira


  • SLC30A3 and SEP15 gene polymorphisms influence the serum concentrations of zinc and selenium in mature adults

    by Tatiane Jacobsen da Rocha, Camila Korb, Jaqueline Bohrer Schuch, Daiani Pires Bamberg, Fabiana Michelsen de Andrade, Marilu Fiegenbaum


  • ACE polymorphism and use of ACE inhibitors: effects on memory performance

    by Jaqueline B. Schuch, Pamela C. Constantin, Vanessa K. da Silva, Camila Korb, Daiani P. Bamberg, Tatiane J. da Rocha, Marilu Fiegenbaum, Alcyr de Oliveira, Luciana A. Tisser, Fabiana M. de Andrade

    Memory is an important cognition function, being fundamental to the development and independence of individuals. Our aim was to investigate the influence apolipoprotein E (APOE) and angiotensin I-converting enzyme (ACE) polymorphism and ACE inhibitors use, besides their interaction on memory performance of healthy subjects over 50 years. The sample consisted of 205 subjects assessed for five types of episodic memory, using Wechsler Memory Scale-Revised (WMS-R), who answered a questionnaire about drug use and were assessed for the ACE insertion/deletion polymorphism and APOE polymorphism. We found no influence of the APOE gene. The use of ACE inhibitors beneficially influenced learning ability scores (p = 0.02). Besides, I allele carriers of ACE polymorphism showed higher verbal memory scores compared with homozygous DD. Also, we observed an interaction influencing learning ability between the ACE polymorphism and the use of inhibitors, the beneficial influence of the I allele was present only in individuals who make use of ACE inhibitors. We conclude that the ACE gene has influence on memory performance, and that this influence is modulated by ACE inhibitors use.


  • The influence on DNA damage of glycaemic parameters, oral antidiabetic drugs and polymorphisms of genes involved in the DNA repair system

    by Bruna Santos da Silva, Diego Luiz Rovaris, Rafaela Milan Bonotto, Jéssica Brasil Figueiredo Meyer, Ramona Elisa Grohe, Magda Susana Perassolo, Roberta de Passos Palazzo, Sharbel Weidner Maluf, Rafael Linden, Fabiana Michelsen de Andrade

    The hyperglycaemia seen in type 2 diabetes mellitus (DM2) is associated with increased oxidative stress and production of reactive oxygen species, both of which are factors that can provoke DNA damage. Notwithstanding, other factors, including medications and individual susceptibility, can also induce this type of DNA lesion. The objective of this study was, therefore, to investigate the influence of glycaemic control, oral antidiabetic drugs (metformin and glibenclamide) and polymorphisms of the XRCC1 and XRCC3 genes on the frequency of DNA damage in DM2 patients, which was accessed by the cytokinesis-block micronucleus cytome and the comet assays on the ex vivo mitogenically stimulated lymphocytes. The 53 people recruited to take part in the study were already on treatment with metformin and were followed for 5 months. Ten of these patients were put on combined treatment with the addition of glibenclamide. It was observed that the greater the plasma metformin concentration, the lower the frequency of micronuclei (MN) in the sample total (P = 0.009) and also that the subset of patients using combined treatment including glibenclamide had a significantly higher MN rate 90 days after starting combined treatment (P = 0.024). In the subset who only took metformin, the rate of MN was significantly higher among carriers of the 399Gln allele on the XRCC1 gene (P = 0.008). In addition, homozygotes for the 241Thr allele exhibited a significant increase in MN in the combined treatment group (P = 0.008). Our results suggest that different combinations of oral antidiabetic drugs and polymorphisms on genes involved in the DNA damage repair system could influence the frequency of this type of chromosome lesion, which can be a useful biomarker for assessing the risk of developing cancer.


  • Open Access

    Influência da interação entre qualidade ambiental e o SNP T102C do gene HTR2A sobre a suscetibilidade à fibromialgia

    by Michelle Mergener, Roze Mary Ribas Becker, Adriana Freitag dos Santos, Geraldine Alves dos Santos, Fabiana Michelsen de Andrade


  • Genetic Influences on Alzheimer’s Disease: Evidence of Interactions Between the Genes APOE, APOC1 and ACE in a Sample Population from the South of Brazil

    by Juliana Fagion Lucatelli, Alessandra Chielle Barros, Vanessa Kappel da Silva, Fernanda da Silva Machado, Pâmela Camini Constantin, Ana Amélia Cipriani Dias, Mara Helena Hutz, Fabiana Michelsen de Andrade

    Alzheimer’s disease is a complex neurodegenerative disorder. Several genes have been suggested as Alzheimer’s susceptibility factors, the apolipoprotein E (APOE) gene being an established susceptibility gene and the genes coding angiotensin-converting enzyme (ACE) and apolipoprotein C1 (APOC1) being considered possible candidate genes for the disease. The objective of this study was to investigate the association of ACE and APOC1 gene polymorphisms with susceptibility to Alzheimer’s disease and dementia in general, both alone and combined with the APOE gene. Forty-seven patients with dementia in general (35 of them with Alzheimer’s disease) and 85 controls were investigated. The haplotypes E*3/−317*ins and E*4/−317*ins of APOE/APOC1 genes were significantly more frequent in the groups with Alzheimer′s disease and dementia in general (P < 0.001). The frequency of the ACE*ins allele was also greater in the groups with Alzheimer’s disease and dementia in general (P = 0.022; P = 0.045), but genotype frequencies were only different in groups without the E*4/−317*ins haplotype (P = 0.012 for Alzheimer’s disease; P = 0.04 for dementia). Our data point to important genetic interactions involved in these diseases.


  • Open Access

    Genomic instability in patients with type 2 diabetes mellitus on hemodialysis

    by Roberta Passos Palazzo, Pamela Brambilla Bagatini, Patrícia Brandt Schefer, Fabiana Michelsen de Andrade, Sharbel Weidner Maluf

    A previous study by our research group evaluated the levels of DNA damage using the comet assay in hemodialysis patients with type 2 diabetes mellitus. The same blood samples were also evaluated using the cytochalasin B micronucleus assay. A comparison of the results of the two assays is presented here. Whole blood samples were collected from 22 type 2 diabetes mellitus patients on hemodialysis and from 22 control subjects. Samples were collected from patients early in the morning on Mondays, before the first weekly hemodialysis session. The cytokinesis-block micronucleus assay (CBMN) was used to evaluate genomic instability. The frequencies of micronuclei and nuclear buds were higher in patients than in controls (p-value = 0.001 and p-value < 0.001, respectively). There was a correlation between the frequency of micronuclei and DNA damage with the results of the comet assay (p-value < 0.001). The difference in the frequency of micronuclei and nuclear buds between patients and controls was more pronounced in the group with higher median comet values than in the group with lower comet values. Our results suggest that the increased rates of DNA damage as measured by the comet assay and influenced by the weekly routine therapy of these patients has a mutagenic effect, thereby increasing the risk of cancer in this group.


  • Open Access

    Interação entre qualidade do meio ambiente, estresse e a variação do gene APOE na determinação da suscetibilidade à fibromialgia

    by Roze Mary Ribas Becker, Vanessa Kappel da Silva, Fernanda da Silva Machado, Adriana Freitag dos Santos, Daiane Cristine Meireles, Michelle Mergener, Geraldine Alves dos Santos, Fabiana Michelsen de Andrade


  • Open Access

    Influência de combinações genéticas nos níveis de HDL-c em uma população do sul do Brasil

    by Fabiana Michelsen de Andrade, Marilu Fiegenbaum, Silvana de Almeida, Mara Helena Hutz

    Low HDL-C levels are important predictors of coronary disease, the first cause of death worldwide. Many factors affect HDL-C levels, such as polymorphisms of genes encoding for key proteins of the reverse cholesterol transport pathway. to investigate the influence of seven polymorphisms of the CETP, APOA1, ABCA1 and SCARB1 genes on HDL-C levels in a southern Brazilian population. the polymorphisms were investigated in a sample of 500 individuals of European descent, but HDL-C levels from only 360 individuals were adjusted for cofactors using multiple linear regressions in the association study. The sample was divided in tertiles according to adjusted HDL-C levels, and allele and haplotype frequencies were compared between the 1st and 3rd tertiles of adjusted HDL-C levels. When combinations of risk alleles were tested, the frequency of allele combinations in three genes (haplotype 1 of APOA1 gene, variant 2S of SCARB1 gene, and allele B1 of CETP gene) was significantly higher in the lower tertile of adjusted HDL-C (28.3%) than in the upper tertile (14.9%; p=0.008), which indicated that the presence of these variants increased 2.26 times the chances of having HDL-C levels below 39.8 mg/dl. these markers, when studied separately, are expected to have a small influence on the characteristic under analysis, but greater influence was detected when the markers were studied in combination. In a population of southern Brazilians, our data showed a significant influence of variant combinations of APOA1, SCARB1 and CETP genes on HDL-c levels.